Measurement of Anticoagulation in Patients on Dabigatran, Rivaroxaban and Apixaban Therapy by Novel Automated Thrombelastography
Background: Direct-acting oral anticoagulants (DOACs) do not require monitoring. Measurement of DOAC effect would be useful in the event of bleeding, trauma, and thromboembolism while on anticoagulation. We evaluated the effectiveness of the investigational DOAC assays on the TEG®6s Hemostasis Analy...
Guardado en:
Autores principales: | Ramin Artang, Joao Dias, Mark Walsh, Kevin P Bliden, Jørn Dalsgaard Nielsen, Maren Anderson, Brain Thurston, Udaya S. Tantry, Jan Hartmann, Paul A Gurbel |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Georg Thieme Verlag KG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/a579f2aee73f467a8bd1e62b2bbf4b46 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Evaluation of the Determination of Dabigatran, Rivaroxaban, and Apixaban in Lupus Anticoagulant-Positive Patients
por: Jana Úlehlová, et al.
Publicado: (2021) -
Temporal trends in initiation of VKA, rivaroxaban, apixaban and dabigatran for the treatment of venous thromboembolism - A Danish nationwide cohort study
por: Caroline Sindet-Pedersen, et al.
Publicado: (2017) -
A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban
por: Frost C, et al.
Publicado: (2014) -
A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban [Corrigendum]
por: Frost C, et al.
Publicado: (2018) -
Anti-Xa Inhibitor-Induced Hemorrhagic Pruritic Rash: A Case Report on Possible Cross-Reactivity Between Apixaban and Rivaroxaban
por: Anis TR, et al.
Publicado: (2021)